- Title:
Schedule One - Life Science REIT plc - Time:
08:00:01 - Date:
1 Nov 2021 - Category:
Capital structure - ID:
8720Q
|
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") |
||||||
|
|
||||||
|
COMPANY NAME: |
||||||
|
Life Science REIT plc (the "Company")
|
||||||
|
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : |
||||||
|
Beaufort House 51 New North Road Exeter EX4 4EP
|
||||||
|
COUNTRY OF INCORPORATION: |
||||||
|
United Kingdom
|
||||||
|
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: |
||||||
|
www.lifesciencereit.co.uk
|
||||||
|
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: |
||||||
|
Life Science REIT plc is a newly incorporated, externally managed, investment company that intends to carry on business as a REIT and, upon admission, will be an "investing company" for the purposes of the AIM Rules. The Company's investment objective is to provide shareholders with an attractive level of total return. The focus will be capital growth whilst also providing a growing level of income by investing primarily in a diversified portfolio of UK properties that are leased or intended to be leased to tenants operating in the life science sector. The investment strategy targets life science clusters that are focused primarily in the "Golden Triangle" of Oxford, Cambridge and London and also selective opportunities in other emerging clusters around the UK.
The Company's external Investment Adviser, Ironstone Asset Management Limited, has assembled a pipeline of potential investment opportunities in accordance with the Company's investing policy, with a number of such opportunities in exclusivity and/or advanced negotiations.
|
||||||
|
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): |
||||||
|
Ordinary shares of 1 pence each ("Ordinary Shares") for which Admission which will be sought: TBC
Issue price per Ordinary Share: 100 pence per Ordinary Share
There are no restrictions as to transfer of Ordinary Shares, subject to compliance with applicable securities law.
No Ordinary Shares to be held in treasury
|
||||||
|
CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: |
||||||
|
Capital to be raised on Admission: TBC
Anticipated market capitalisation on Admission: TBC
|
||||||
|
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: |
||||||
|
TBC
|
||||||
|
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: |
||||||
|
N/A
|
||||||
|
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): |
||||||
|
|
||||||
|
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): |
||||||
|
TBC
|
||||||
|
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: |
||||||
|
None.
|
||||||
|
(i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: |
||||||
|
(i) 31 December (ii) 31 July 2021 (iii) 01 August 2021 to 31 December 2021 (audited) - published by 30 June 2022; 6 month period ending 30 June 2022 (unaudited) - published by 30 September 2022; 12 month period ending 31 December 2022 (audited) - published by 30 June 2023
|
||||||
|
EXPECTED ADMISSION DATE: |
||||||
|
Mid November 2021
|
||||||
|
NAME AND ADDRESS OF NOMINATED ADVISER: |
||||||
|
Panmure Gordon (UK) Limited One New Change London EC4M 9AF United Kingdom
|
||||||
|
NAME AND ADDRESS OF BROKER: |
||||||
|
Panmure Gordon (UK) Limited One New Change London EC4M 9AF United Kingdom
Jefferies International Limited 100 Bishopsgate London EC2N 4JL
|
||||||
|
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: |
||||||
|
A copy of the Admission Document containing full details about the applicant and the admission of its securities is available on the Company's website at: www.lifesciencereit.co.uk
|
||||||
|
THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY |
||||||
|
AIC Code of Corporate Governance
|
||||||
|
DATE OF NOTIFICATION: |
||||||
|
1 November 2021
|
||||||
|
NEW/ UPDATE: |
||||||
|
New
|
Schedule One - Life Science REIT plc08:00:011 Nov 2021Capital structure8720Q